Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare spending and emergence of efficacious newer anti-epileptic drugs. Furthermore, co-morbidities associated with epilepsy such as depression and anxiety are on rise and major players are investing in the research and awareness programs for reduction of these co-morbidities along with epilepsy. For instance, Sanofi, S.A. invests major amounts into awareness programs in regions with emerging economies such as Latin America, Africa, and Asia Pacific. The company offers products with price adjustments in these regions to increase the access to these treatments. The investments by major players in the pipeline over the past few years have shown positive results in terms of product launches such as Vimpat drug approvals in Europe and Japan in the treatment of partial onset seizures for UCB Pharma in 2016.

Market Dynamics

Major market players are focusing on providing viable treatment options in patients suffering from refractory epilepsy or drug resistant epilepsy. The add-on or adjunctive therapies designed by market players offer significant positive results with relatively less side effects. This, in turn, is expected to boost the market growth rate for anti-epileptic drugs. Some notable drugs in the pipeline such as Lyrica (Pregabalin), are showing potential therapeutic effects with fewer drug interactions, improved side effect profiles, and enhanced overall safety. This addresses a major need in the AED market, since most of the older treatments such as carbamazepine, valproate, and phenytoin, although effective, have very poor safety profiles and are not well-tolerated by pediatric patients.

Market Taxonomy

This report segments the global Anti-Epileptic Drugs for Pediatrics Market on the basis of drug type and region. On the basis of drug type, the global Anti-Epileptic Drugs for Pediatrics Market is segmented into 1^stgeneration, 2^nd generation, and 3^rd generation.

Key features of the study:

• This report provides in-depth analysis of Anti-Epileptic Drugs for Pediatrics Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2016 – 2025), considering 2015 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global Anti-Epileptic Drugs for Pediatrics Market on the basis of the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Mylan N.V.*, Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.
• Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global Anti-Epileptic Drugs for Pediatrics Market report caters to various stakeholders in this industry, including investors, suppliers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Anti-Epileptic Drugs for Pediatrics Market

Detailed Segmentation:

• Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Global Anti-Epileptic Drugs for Pediatrics Market, By Geography:
• North America
• U.S.
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Canada
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Europe
• U.K.
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Germany
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Italy
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• France
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Russia
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Rest of Europe
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Asia-Pacific
• China
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• India
• By Drug Type:
• 1^st Generation
• 2^nd Generation

• 3^rd Generation

• Japan
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• ASEAN
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Australia
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• South Korea
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Rest of Asia Pacific
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Latin America
• Brazil
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Mexico
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Rest of Latin America
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Middle East
• GCC
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Israel
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Africa
• North Africa
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Central Africa
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• South Africa
• By Drug Type:
• 1^st Generation
• 2^nd Generation
• 3^rd Generation

• Competitive Landscape
• Heat Map Analysis
• Market Share Analysis
• Company Profiles
• Mylan N.V.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
• Cephalon, Inc.
• GlaxoSmithKline plc
• Janssen Pharmaceuticals
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• UCB Pharma Limited
• Sunovion Pharmaceuticals Limited
• Valeant Pharmaceuticals International, Inc.
• Zogenix
• GW Pharmaceuticals
• Insys
• Zynerba
• Analyst Views
• Section
• References
• Research Methodology
• About Us and Sales Contact

*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025”.